FNY Investment Advisers LLC Takes Position in Medtronic PLC $MDT

Key Points

• FNY Investment Advisers LLC acquired a stake in Medtronic PLC worth approximately $374,000 by purchasing 4,300 shares in the second quarter.
• Several institutional investors significantly increased their positions in Medtronic, with Brighton Jones LLC boosting its stake by 1,368.0% in the 4th quarter.
• Medtronic reported earnings of $1.26 per share for the last quarter, exceeding analyst estimates and setting FY 2026 guidance at 5.600-5.660 EPS.

FNY Investment Advisers LLC acquired a new stake in Medtronic PLC (NYSE:MDT - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 4,300 shares of the medical technology company's stock, valued at approximately $374,000.

Other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC boosted its position in Medtronic by 1,368.0% during the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company's stock valued at $3,194,000 after buying an additional 37,265 shares during the period. GAMMA Investing LLC boosted its position in Medtronic by 41.1% during the 1st quarter. GAMMA Investing LLC now owns 15,882 shares of the medical technology company's stock valued at $1,427,000 after buying an additional 4,626 shares during the period. GHP Investment Advisors Inc. boosted its position in Medtronic by 2.5% during the 1st quarter. GHP Investment Advisors Inc. now owns 47,458 shares of the medical technology company's stock valued at $4,265,000 after buying an additional 1,157 shares during the period. International Assets Investment Management LLC boosted its position in Medtronic by 1.2% during the 1st quarter. International Assets Investment Management LLC now owns 14,597 shares of the medical technology company's stock valued at $1,312,000 after buying an additional 177 shares during the period. Finally, Moran Wealth Management LLC boosted its position in Medtronic by 19.1% during the 1st quarter. Moran Wealth Management LLC now owns 159,727 shares of the medical technology company's stock valued at $14,353,000 after buying an additional 25,602 shares during the period. Hedge funds and other institutional investors own 82.06% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on MDT shares. BTIG Research reissued a "neutral" rating on shares of Medtronic in a research report on Friday, July 11th. Stifel Nicolaus upped their price objective on shares of Medtronic from $90.00 to $105.00 and gave the stock a "hold" rating in a report on Thursday, October 9th. Evercore ISI upped their price objective on shares of Medtronic from $103.00 to $106.00 and gave the stock an "outperform" rating in a report on Tuesday, July 8th. Mizuho upped their price objective on shares of Medtronic from $98.00 to $100.00 and gave the stock an "outperform" rating in a report on Wednesday, July 16th. Finally, Morgan Stanley restated an "overweight" rating and issued a $107.00 price objective (up from $98.00) on shares of Medtronic in a report on Tuesday, July 15th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $102.82.

Medtronic Stock Up 0.0%

Shares of Medtronic stock opened at $95.84 on Thursday. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.01 and a quick ratio of 1.50. The company has a 50-day moving average of $94.26 and a 200 day moving average of $89.17. The firm has a market cap of $122.93 billion, a price-to-earnings ratio of 26.40, a PEG ratio of 2.52 and a beta of 0.78. Medtronic PLC has a 1 year low of $79.29 and a 1 year high of $99.37.

Medtronic (NYSE:MDT - Get Free Report) last issued its quarterly earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.03. The company had revenue of $8.58 billion during the quarter, compared to analyst estimates of $8.37 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. Medtronic's quarterly revenue was up 7.7% compared to the same quarter last year. During the same period last year, the business earned $1.23 EPS. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. As a group, sell-side analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 17th. Investors of record on Friday, September 26th were paid a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 3.0%. The ex-dividend date was Friday, September 26th. Medtronic's dividend payout ratio (DPR) is presently 78.24%.

Insider Activity

In other Medtronic news, EVP Harry Skip Kiil sold 8,605 shares of the firm's stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total transaction of $788,045.90. Following the completion of the sale, the executive vice president directly owned 35,615 shares in the company, valued at approximately $3,261,621.70. This trade represents a 19.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director William R. Jellison acquired 2,500 shares of Medtronic stock in a transaction on Monday, August 25th. The shares were purchased at an average price of $92.37 per share, with a total value of $230,925.00. Following the completion of the purchase, the director owned 5,000 shares in the company, valued at $461,850. This represents a 100.00% increase in their position. The disclosure for this purchase can be found here. 0.26% of the stock is owned by company insiders.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.